Gut microbes: From bugs to drugs

American Journal of Gastroenterology

Volumn 105, Issue 2, 2010, Pages 275-279

  Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

DIGESTIVE SYSTEM; ECOSYSTEM; GASTROENTEROLOGY; HEALTH CARE; HOST PARASITE INTERACTION; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

DIET; DRUG DISCOVERY; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; METAGENOME; MICROBIAL INTERACTIONS; PROBIOTICS;

EID: 76349083598     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.729     Document Type: Review

References (35)

1. Skrabanek P. Risk factor epidemiology:Science or non-science? In:False Premises False Promises. Taragon Press:Whithorn, 1999, pp 153-63.
2. Cho JH. The genetics and immunopathogenesis of infl ammatory bowel disease. Nat Rev Immunol 2008;8:458-466
3. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008;9:9-14.
4. Bernstein CN, Shanahan F. Disorders of a modern lifestyle:reconciling the epidemiology of infl ammatory bowel diseases. Gut 2008;57:1185-1191
5. O'Hara AM, Shanahan F. The gutflora as a forgotten organ. EMBO Rep, 2006, 7, 688-693
6. Shanahan F. Therapeutic implications of manipulating and mining the microbiota. J Physiol 2009;587 (Pt 17):4175-4179
7. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-323
8. Turnbaugh PJ, Ley RE, Hamady M et al. The human microbiome project. Nature 2007;449:804-810
9. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101:15718-15723
10. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008;455:1109-1113
11. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Design 2009;15:1546-1558
12. Li M, Wang B, Zhang M et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105:2117-2122
13. Shanahan F, Stanton C, Ross P et al. Pharmabiotics:bioactives from mining host-microbe-dietary interactions. Funct Food Rev 2009;1:1-6.
14. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in infl ammatory bowel disease:a review of clinical trials. Proc Nutr Soc 2007;66:307-315
15. Corr SC, Li Y, Riedel CU et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007;104:7617-7621
16. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis:a randomised, double-blind, placebocontrolled trial. Lancet 2008;371:651-9. Erratum in:Lancet 2008;371:1246.
17. Sonnenburg JL, Chen CTL, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol 2006;4:2213-2226
18. Mahowald MA, Rey FE, Seedorf H et al. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci USA 2009;106:5859-5864
19. Wall R, Ross RP, Shanahan F et al. The metabolic activity of the enteric microbiota infl uences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 2009;89:1393-1401
20. Shoda R, Matsueda K, Yamato S et al. Epidemiologic analysis of Crohn disease in Japan:increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996;63:741-745
21. Caskey CT. The drug development crisis:effi ciency and safety. Annu Rev Med 2007;58:1-16.
22. Parsons ME, Garner A. Drug development in gastroenterology-the changing view of industry. Aliment Pharmacol Ther 1995;9:457-463
23. Bernstein AS, Ludwig DS. The importance of biodiversity to medicine. JAMA 2008;200:2297-2299
24. Shanahan F, Kiely B. The gut microbiota and disease-an inner repository for drug discovery. Drug Discov Today Th er Strateg 2007;4:195-200.
25. Ivanov II, Frutos Rde L, Manel N et al. Specifi c microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008;4:337-349
26. Bouskra D, Bré zillon C, Bérard M et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008;456:507-510
27. Mazmanian SK, Liu CH, Tzianabos AO et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122:107-118
28. Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-infl ammatory eff ects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528
29. Fujiya M, Musch MW, Nakagawa Y et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 2007;1:299-308.
30. Yan F, Cao H, Cover TL, Whitehead R et al. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007;132:562-575
31. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal infl ammatory disease. Nature 2008;453:620-625
32. Cotter PD, Hill C, Ross RP. Bacteriocins:developing innate immunity for food. Nat Rev Microbiol 2005;3:777-788
33. Burton JP, Chilcott CN, Moore CJ et al. A preliminary study of the eff ect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 2006;100:754-764
34. Rea MC, Clayton E, O ' Connor PM et al. Antimicrobial activity of lacticin 3147 against clinical Clostridium diffi cile strains. J Med Microbiol 2007;56:940-946
35. Kelly CP, LaMont JT. Clostridium diffi cile-more difficult than ever. N Engl J Med 2009;359:1932-1940